What are Evommune 's total assets?

Evommune (EVMN) holds $7.2M in total assets.

How much debt does Evommune have?

Evommune carries $2.0M in total debt against -$4.5M of shareholders' equity, a debt-to-equity ratio of 1.36.

How much cash does Evommune have?

Evommune holds $1.1M in cash and equivalents.

Can Evommune cover its short-term obligations?

Its current ratio is 1.20 — current assets exceed current liabilities.

Where does Evommune 's balance sheet data come from?

Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Evommune EVMN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	——	——	——	——	——
Accounts receivable, net	——	——	——	——	$351.45K-8.1%
Inventories	——	——	——	——	$1.82M+6.5%
Raw materials	——	——	——	——	——
Finished goods	——	——	——	——	——
Prepaid expenses and other current assets	——	——	——	——	——
Derivative assets	——	——	——	——	——
Materials and supplies	——	——	——	——	——
Total current assets	——	——	——	——	——
Property and equipment, net	——	——	——	——	——
Machinery and equipment	——	——	——	——	——
Furniture, fixtures and equipment	——	——	——	——	——
Accumulated depreciation	——	——	——	——	——
Operating lease right-of-use assets	——	——	——	——	——
Goodwill	——	——	——	——	——
Intangible assets, net	——	——	——	——	——
Total noncurrent assets	——	——	——	——	——
Total assets	——	——	——	——	——
Accounts payable	——	——	——	——	——
Accrued expenses	——	——	——	——	——
Current portion of long-term debt	——	——	——	——	——
Operating lease liabilities, current	——	——	——	——	——
Short-term borrowings	——	——	——	——	——
Derivative liabilities	——	——	——	——	——
Total current liabilities	——	——	——	——	——
Long-term debt	——	——	——	——	——
Operating lease liabilities, non-current	——	——	——	——	——
Operating Lease Liabilities (Total)	——	——	——	——	——
Senior unsecured notes, net	——	——	——	——	——
Total noncurrent liabilities	——	——	——	——	——
Total liabilities	——	——	——	——	——
Common stock	——	——	——	——	——
Additional paid-in capital	——	——	——	——	——
Retained earnings	——	——	——	——	——
Total stockholders' equity	-$4.51M-393%	$1.54M+155%	$604.67K+135%	$257.16K+68.1%	$153.01K—
Total liabilities and stockholders' equity	——	——	——	——	——
Allowance for Doubtful Accounts	——	——	——	——	——
Other current assets	——	——	——	——	——
Inventory Valuation Adjustments	——	——	——	——	——
Capitalized Computer Software, Net	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Finite Lived Intangible Assets - Gross	——	——	——	——	——
Net Investment in Lease	——	——	——	——	——
Intangible assets — net	——	——	——	——	——
Other intangible assets—net	——	——	——	——	——
Machinery and equipment	——	——	——	——	——
Operating lease right-of-use assets	——	——	——	——	——
Property, plant and equipment at cost	——	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	——	——	——	——	——
Software and Technology Licenses, Net	——	——	——	——	——
Other Commercial Liabilities	——	——	——	——	——
Accounts payable and other current liabilities (Note 11)	——	——	——	——	——
Accrued Liabilities, Current	——	——	——	——	——
Derivative Liability, Current	——	——	——	——	——
Government Loans Current	——	——	——	——	——
Liability With Conditional Timing	——	——	——	——	——
Revolving credit facility	——	——	——	——	——
Term loan	——	——	——	——	——
Other accrued liabilities	——	——	——	——	——
Other short-term debt	——	——	——	——	——
Derivative Liabilities - Fair Value	——	——	——	——	——
Line of Credit Outstanding	——	——	——	——	——
Convertible Debt (Non-Current)	——	——	——	——	——
Debt Instrument Face Amount	——	——	——	——	——
Debt Instrument Stated Interest Rate	——	——	——	——	——
Debt Maturity - 2027	——	——	——	——	——
Debt Maturity - Thereafter	——	——	——	——	——
Derivative Liabilities (Non-Current)	——	——	——	——	——
Total debt	——	——	——	——	——
Common Stock Par Value Per Share	——	——	——	——	——
Common Stock Shares Issued	——	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	——	——	——	——	——
Cumulative Cost Basis	——	——	——	——	——
Gross Assets/Liabilities	——	——	——	——	——
Line of Credit Remaining Borrowing Capacity	——	——	——	——	——
Accrued Bonuses Current And Noncurrent	——	——	——	——	——
Accrued Compensation Shares Earned But Not Issued	——	——	——	——	——
Allowance for doubtful accounts	——	——	——	——	——
Amortization Expense	——	——	——	——	——
Amount Of Judgment Threshold	——	——	——	——	——
Assessed Value Of Warrants	——	——	——	——	——
Cash FDIC Insured Amount	——	——	——	——	——
Class of Warrant or Right, Outstanding	——	——	——	——	——
Common stock, par value (in dollars per share)	——	——	——	——	——
Common Stock Share To Be Issued	——	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——	——
Common stock, shares issued (in shares)	——	——	——	——	——
Common Stock, Shares, Outstanding	——	——	——	——	——
Convertible Debt	——	——	——	——	——
Convertible debentures	——	——	——	——	——
Effective conversion price (per $1,000 of principal amount) per share	——	——	——	——	——
Debt issuances	——	——	——	——	——
Deposits In Transit	——	——	——	——	——
Derivative Assets Liabilities At Fair Value Net	——	——	——	——	——
Derivative Liability	——	——	——	——	——
Derivative Liability, Noncurrent	——	——	——	——	——
Finance Charge	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	——	——	——	——	——
2028	——	——	——	——	——
2030	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
Gross Carrying Amount	——	——	——	——	——
Government Loans Net Of Noncurrent Liabilities	——	——	——	——	——
Raw materials	——	——	——	——	——
Lease Liability Imputed Interests	——	——	——	——	——
Lease Liability Payments Due	——	——	——	——	——
Lessee Lease Liability Payments Due Year Five	——	——	——	——	——
Lessee Lease Liability Payments Due Year Four	——	——	——	——	——
Lessee Lease Liability Payments Due Year Three	——	——	——	——	——
Lessee Lease Liability Payments Due Year Two	——	——	——	——	——
Lessee Liability Payments Due Next Twelve Months	——	——	——	——	——
2028	——	——	——	——	——
2029	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
Thereafter	——	——	——	——	——
2027	——	——	——	——	——
Percentage Of Effective Borrowing Rate	——	——	——	——	——
Preferred Shrares Liabilities	——	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	——	——	——	——	——
Preferred Stock, Shares Authorized	——	——	——	——	——
Prepaids And Deposits Current	——	——	——	——	——
Present Value Of Lease Liabilities	——	——	——	——	——
Recognized Expenses Of Warrants	——	——	——	——	——
Right Of Use Assets	——	——	——	——	——
Right Of Use Assets Recognized Gross	——	——	——	——	——
Share price (in dollars per share)	——	——	——	——	——
Working Capital	——	——	——	——	——
Purchase Commitments - Due Next Year	——	——	——	——	——
Purchase Obligation	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Evommune .

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Evommune 's total assets?: Evommune (EVMN) holds $7.2M in total assets.
How much debt does Evommune have?: Evommune carries $2.0M in total debt against -$4.5M of shareholders' equity, a debt-to-equity ratio of 1.36.
How much cash does Evommune have?: Evommune holds $1.1M in cash and equivalents.
Can Evommune cover its short-term obligations?: Its current ratio is 1.20 — current assets exceed current liabilities.
Where does Evommune 's balance sheet data come from?: Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.